SHARE PRICE ASX:IHL $

Clinical Trials IHL has commenced the full drug discovery process for cannabinoid products for OSA, TBI, SAARDS & TMJD IHL has commenced the full drug discovery process for cannabinoid products for OSA, TBI, SAARDS & TMJD

Clinical programs underway in 2020

Incannex is undertaking four clinical trials in 2020 for the creation of four distinct products with clinical evidence.

Under the guidance of our new medical advisory board, IHL has commenced the full drug discovery process for cannabinoid products for OSA, TBI, SAARDS and TMJD.

The expanded clinical program will create 4 novel products for which patents have been or are in the process of being filed.

  • IHL-42X | OSA Obstructive Sleep Apnea
  • IHL-216A | TBI Traumatic Brain Injury
  • IHL-675A | SAARDS Sepsis Associated Acute Respiratory Distress Syndrome
  • IHL-493C | TMJD Temporomandibular Joint Dysfunction
Sinuses - Breathing / Human Anatomy

IHL-42X | OSA 


Obstructive Sleep Apnea

Learn More

IHL-216A | TBI 


Traumatic Brain Injury

Learn More
b1921029beb35ebb6bc80b1bd5c043_jumbo

IHL-675A | SAARDS 


Sepsis Associated Acute Respiratory Distress Syndrome

Learn More
TMJ_1

IHL-493C | TMJD 


Temporomandibular Joint Dysfunction

Learn More